New vaccine technologies are showing promise not only in fighting viruses but also in cancer treatment by activating T cells for immunotherapy. These nanoparticle-based formulations can deliver drugs effectively to the brain, potentially improving treatments for Alzheimer's and Parkinson's. Additionally, the design of these vaccines allows for adaptability against evolving virus variants, with a target timeline of two to five years for clinical application.
